Investigations Into the Analysis of Intact Drug Conjugates In

Total Page:16

File Type:pdf, Size:1020Kb

Investigations Into the Analysis of Intact Drug Conjugates In View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Ghent University Academic Bibliography Received: 30 October 2019 Revised: 7 February 2020 Accepted: 8 February 2020 DOI: 10.1002/dta.2779 RESEARCH ARTICLE Investigations into the analysis of intact drug conjugates in animal sport doping control – Development and assessment of a rapid and economical approach for screening greyhound urine Bob Gray1,2 | Lisa Tuckley1 | Charlotte Cutler1 | Simon Biddle1 | Simon Hudson1 | Simon Gower3 | Lynn Vanhaecke2,4 1Bob Gray, LGC Ltd, Newmarket Road, Fordham, Cambridgeshire, UK Abstract 2Laboratory of Chemical Analysis, Department Animal sport doping control laboratories are constantly reviewing ways in which they of Veterinary Public Health and Food Safety, can improve their service offering whilst ensuring that they remain economically via- Ghent University, Merelbeke, Belgium 3Greyhound Board of Great Britain, 6 New ble. This paper describes the development and assessment of a rapid and economical Bridge Street, London, UK method for the detection of intact glucuronide conjugates of three anabolic steroids 4 School of Biological Sciences, Institute for and their metabolites along with three corticosteroids in canine urine. The analysis of Global Food Security, Queen's University, Belfast, UK intact drug conjugates for animal sport doping control is generally not performed rou- tinely as it presents a number of analytical challenges, not least of which is the lack of Correspondence Bob Gray, LGC Ltd, Newmarket Road, availability of appropriate reference standards. Here, we report the development of a Fordham, Cambridgeshire, CB7 5WW, UK. UHPLC–MS/MS method using APCI in the negative ion mode for the detection of Email: [email protected] intact phase II conjugates, including the importance of in vitro incubations in order to Funding information provide appropriate reference materials. Cross-validation of the developed method Greyhound Board of Great Britain (GBGB) demonstrated that the detection capability of the intact phase II conjugates of stanozolol, boldenone, nandrolone, and their metabolites along with the corticoste- roids dexamethasone and methylprednisolone was equivalent to that achieved in routine race-day screens. The new process has been in operation for approximately 2 years and has been used to analyze in excess of 13500 canine urine samples, resulting in a number of positive screening findings. To the best of our knowledge, this is the first reported use of a routine screen for intact drug conjugates within ani- mal sport doping control. KEYWORDS anabolic steroids, doping control, glucuronide conjugates, greyhound urine, UPLC-MS/MS 1 | INTRODUCTION these animals would then be sold on to new owners prior to com- mencing a racing career. With the sale price being dependent upon In 2011, the Greyhound Board of Great Britain (GBGB) instigated the their performance whilst in training, it is clear to see how improved Point of Registration (POR) testing program.1 At that time there was a performance could result in an increased sale price. perception within the sport that some animals were being adminis- The POR test was introduced in order to provide a layer of pro- tered long acting prohibited substances, such as anabolic steroids, in tection against this practice, to increase buyer confidence when pur- order to gain a performance improvement whilst in training. Many of chasing racing greyhounds, and to demonstrate an on-going Drug Test Anal. 2020;1–12. wileyonlinelibrary.com/journal/dta © 2020 John Wiley & Sons, Ltd. 1 2 GRAY ET AL. commitment to the integrity of the sport. From May 2011 onwards, derivatization and subsequent analysis by gas chromatography mass all animals that were taken to a racecourse for microchipping and reg- spectrometry (GC–MS), which has traditionally been the analytical istration to race were required to have a urine sample collected at the technique of choice for the detection of anabolic steroids and their same time.1 This urine sample was collected in a tamper evident sam- metabolites in animal sport doping control.2-5 In addition, phase I ple kit, given a unique and anonymized sample identifier and subse- metabolites are usually more readily available as reference standards, quently transported to the laboratory at LGC for long-term frozen which greatly assists with method development. storage. Whilst relatively sparse, there are previous reports on the detec- If a racing greyhound was subsequently tested positive for a tion of intact phase II conjugates of anabolic steroids from animal prohibited substance in the first 6 months from the time of its regis- sport doping control laboratories. As early as 1983, Dumasia et al. tration then the POR sample would be removed from long-term stor- reported on the successful detection of intact sulfate conjugated age and analyzed in order to determine if the substance was present boldenone in equine urine6 using fast-atom bombardment MS, but at the time of registration. The results from both tests would then be the method was hampered by high levels of matrix interference and available to the GBGB for consideration at any subsequent enquiry. was not suitable for routine testing. In 2002, the detection of endoge- This approach allowed the GBGB to collect samples from all regis- nous intact boldenone sulfate in the urine of colts was reported by tered animals but was also relatively low cost with just a small storage the group of Ho et al.7 This work subsequently led to the establish- fee being applicable to all samples and an analysis fee only for those ment of an internationally agreed threshold for the detection of samples that required testing. boldenone in the urine of intact male horses. Grace et al.8 reported a In 2016, the GBGB proposed a change in the way in which the method for the detection of intact sulfate conjugates of both samples collected as part of the POR program were processed. The boldenone and nandrolone in the urine of male horses. The authors new approach would see all samples analyzed within 10 working days overcame an issue of interference from high concentrations of sulfate of their receipt in the laboratory for a selection of prohibited sub- conjugates of the female sex hormones estrone and estradiol by selec- stances known to be of long duration. As this test was to be applied tive hydrolysis of aryl sulfates using glucuronidase from Helix pomatia. to all animals newly registered with the GBGB, there was a require- This approach allowed for the targeted hydrolysis of the aryl sulfates ment to make the analytical procedure as cost effective as possible of estrone and estradiol without any significant hydrolysis of the alkyl and therefore the number of analytes covered was restricted to a sulfates of nandrolone and boldenone. By following up this highly number of key compounds of interest. The analytes selected for inclu- targeted hydrolysis approach with a targeted solid phase extraction, sion in the first iteration of the method were the anabolic steroids the newly liberated “free” phenolic steroids were removed to waste boldenone, nandrolone, and stanozolol along with the corticosteroids and the retained nandrolone and boldenone sulfates subsequently dexamethasone, betamethasone, and methylprednisolone. This group eluted. of analytes was based upon the results obtained from the routine The analysis of intact conjugated anabolic steroids has a number screening of race-day urine samples performed at LGC and following of potential advantages, not least of which is the elimination of the consultation with the GBGB. enzyme hydrolysis step, which is both timely and costly due to the The aim of the new method was to provide equivalent coverage, requirement for high quality purified enzyme solution. There are also in terms of detection capability, to that achieved in the routine concerns that variation in the hydrolysis step from one batch to screens in place at LGC for anabolic steroids and corticosteroids in another may lead to unreliable and unreproducible results.9,10 In addi- race-day greyhound urine. As such there was no requirement to quan- tion, when employing liquid chromatography tandem mass spectrome- titatively validate the method but rather to assess its performance try, the intact conjugates ionize readily in both the positive and against the current screening protocols, which we termed cross- negative mode without the need for a time consuming derivatization validation throughout the work. An adverse screening finding from step. As such, the analysis of intact phase II conjugates has been the POR test results in the dog being prevented from racing until such investigated in human urine samples, primarily for doping control pur- time as a negative result is obtained. poses.11-17 This approach has gained acceptance and is used to com- Urine has always been the matrix of choice for greyhound doping plement the more traditional approach to steroid analysis in urine control as it is easy to collect and generally contains higher analyte samples. Whilst the detection of intact drug conjugates, particularly of concentrations than blood. As such, the methods employed by animal anabolic steroids, is reported for human sport doping control, there is sport doping control laboratories are based upon the detection of very little information available on its routine use in animal sport dop- drugs in urine and in many cases this requires the extraction and anal- ing control. ysis of phase I and phase II metabolites. In the dog, conjugation with Whilst offering undoubted benefits, the successful development glucuronic acid is the most important phase II metabolic reaction of of methods for the detection of intact phase II conjugates is compli- anabolic steroids.2-4 Therefore, the analysis of anabolic steroids in cated by the lack of availability of appropriate reference standards. greyhound urine is usually undertaken following enzymatic hydrolysis For those compounds for which reference materials are not commer- using β-glucuronidase enzymes to cleave the glucuronic acid and to cially available the synthesis of phase II steroid conjugates by in vitro release the phase I metabolites.
Recommended publications
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Expression of Recombinant Human Androgen Receptor and Its Use for Screening Methods
    Institut für Physiologie FML Weihenstephan Technische Universität München Expression of recombinant human androgen receptor and its use for screening methods Ellinor Rose Sigrid Bauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. B. Hock Prüfer der Dissertation: Univ.-Prof. Dr. H. H. D. Meyer Univ.-Prof. Dr. H. Sauerwein (Rheinische Friedrich-Wilhelms-Universität Bonn) Die Dissertation wurde am 31.10.2002 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 03.12.2002 angenommen. Introduction Content 1. INTRODUCTION ..................................................................................................................................... 5 1.1. ENDOCRINE DISRUPTERS 5 1.2. ANDROGENS AND ANTIANDROGENS 7 1.2.1. DEFINITIONS 7 1.2.2. MODE OF ACTION 8 1.3. STRUCTURES OF ENDOCRINE DISRUPTERS 10 1.4. STRATEGIES FOR MONITORING ANDROGEN ACTIVE SUBSTANCES 13 1.4.1. IN VIVO METHODS 13 1.4.2. IN VITRO METHODS 15 1.5. OBJEKTIVE OF THE STUDIES 18 2. MATERIALS AND METHODS ................................................................................................................. 19 2.1. PREPARATION OF RECEPTORS 19 2.2. ASSAY SYSTEMS 19 2.2.1. IN SOLUTION AR ASSAY 19 2.2.2. IMMUNO-IMMOBILISED RECEPTOR ASSAY (IRA) 20 2.2.3. PR AND SHBG ASSAYS 21 2.2.4. DATA EVALUATION 21 2.3. ANALYTES 22 3. RESULTS AND DISCUSSION ................................................................................................................. 23 3.1. DEVELOPMENT OF NEW ASSAY SYSTEMS 23 3.1.1. BAR ASSAY 23 3.1.2. CLONING OF THE HUMAN AR AND PRODUCTION OF FUNCTIONAL PROTEIN 24 3.1.3. DEVELOPMENT OF A SCREENING ASSAY ON MICROTITRE PLATES (IRA) 25 3.2.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Ranvet's Filybol
    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • The Metabolism of Anabolic Agents in the Racing Greyhound
    The Metabolism of Anabolic Agents In the Racing Greyhound A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy by Mr. Keith Robert Williams, B.Sc. July 1999 Department of Forensic Medicine & Science University of Glasgow Copyright © 1999 by Keith R. Williams. All rights reserved. No part o f this thesis may be reproduced in any forms or by any means without the written permission o f the author. I ProQuest Number: 13833925 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833925 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GLASGOW UNIVERSITY LIBRARY 111-X (coK To my parents for all their help, support and encouragement i Table of Contents i List of Figures V List of Tables VIII Summary IX Chapter 1: Drugs in Sport ...............................................................................................................................1 Introduction .................................................................................................................................................
    [Show full text]
  • MSM Chapter 1200 3/1/21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.
    [Show full text]
  • Ranvet's Filybol
    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 01/24/2018 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified uses Non-virilising anabolic combination for fillies, mares, colts and stallions. Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Legend: Annex VI Label elements Hazard pictogram(s) SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 01/24/2018 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
    [Show full text]
  • Number HS 2007 Description Applied Tariff Rate Or Preferential Tariff Rate
    Applied Tariff Rate or Preferential Tariff Rate over Ex-out / Number HS 2007 Description the NMF Tariff Note Product Rate for Specification Colombia under the FTA since 2010 1 0101.10.01 Horses Ex. 2 0101.10.99 Other Ex. 3 0101.90.01 Jump or race horses Ex. 4 0101.90.02 Non pedigreed breeding horses Ex. "Horses for slaughter, when 5 0101.90.03 imported by Federally Inspected Ex. Establishment type packers." 6 0101.90.99 Other Ex. 7 0102.10.01 Pure-bred breeding animals Ex. 8 0102.90.01 Dairy cows Ex. "With pedigree or High Registrating Certificate, 9 0102.90.02 Ex. excluding those of code 0102.90.01" "Bovines for slaughter, when 10 0102.90.03 imported by Industrial de Ex. Abastos." 11 0102.90.99 Other Ex. 12 0103.10.01 Pure-bred breeding animals Ex. With pedigree or High 13 0103.91.01 Ex. Registrating Certificate. 14 0103.91.02 Peccaries Ex. 15 0103.91.99 Other Ex. With pedigree or High 16 0103.92.01 Ex. Registrating Certificate. "Weighing more than 110 kg., 17 0103.92.02 excluding those of codes Ex. 0103.92.01 and 0103.92.03." 18 0103.92.03 Peccaries Ex. 19 0103.92.99 Other Ex. With pedigree or High 20 0104.10.01 Ex. Registrating Certificate. 21 0104.10.02 For slaughter. Ex. 22 0104.10.99 Other Ex. With pedigree or High 23 0104.20.01 Ex. Registrating Certificate. 24 0104.20.99 Other Ex. When do not require food 25 0105.11.01 28% during their transportation Newly born breeding birds, with High Registrating Certificate, for 26 0105.11.02 28% imports of up to 18,000 heads per transaction.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Permanent Ban on Anabolic Androgenic Steroids From
    Permanent Ban on Anabolic Androgenic Steroids to be introduced into the Greyhounds Australasia Rules Warning to trainers – Anabolic Androgenic Steroids (AAS) usage in greyhounds On 1 January 2016, Greyhounds Australasia will introduce Anabolic Androgenic Steroids to the list of Permanently Banned Prohibited Substances within GAR 79A (2) xx. as follows: “Anabolic androgenic steroids excluding those that are defined as an exempted substance pursuant to GAR 1.” The relevant exempted substance listed within GAR 1 is as follows: “Ethyloestrenol when administered orally to a greyhound bitch and where it has been prescribed by a veterinary surgeon for the sole purpose of regulating or preventing oestrus in that bitch.” Participants are advised that in accordance with GAR 79A they must never possess, acquire, attempt to acquire, administer or allow to be administered to any greyhound from birth until retirement, any anabolic androgenic steroid, excluding ethyloestrenol where it is appropriately prescribed for use as an oestrous suppressant in females. “Anabolic androgenic steroids” include those that are currently registered in Australia by the APVMA such as boldenone, ethyloestrenol, methandriol, nandrolone, stanozolol and testosterone. Others include but are not limited to 1- androstenediol; 1-androstenedione; bolandiol; bolasterone; boldione; calusterone; clostebol; danazol; dehydrochlormethyltestosterone; desoxymethyltestosterone; drostanolone; fluoxymesterone; formebolone; furazabol; gestrinone; 4-hydroxytestosterone; mestanolone; mesterolone;
    [Show full text]